Shanghai Helioson Pharmaceutical Co. Ltd. has identified molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1) and/or zinc finger protein Aiolos (IKZF3) degradation inducers reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Metastasis is the leading cause of mortality in patients with small-cell lung cancer (SCLC), with limited therapeutic options available. SCLC is characterized by a high proliferation rate, early metastasis and poor prognosis.
Alentis Therapeutics AG has obtained IND clearance from the FDA for ALE.P02, an anti-Claudin-1 (CLDN1) antibody-drug conjugate (ADC) with a tubulin inhibitor payload.
Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged phosphatidylinositol 3-kinase α (PI3Kα) (E545K mutant) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Researchers at Anadolu University and Bilecik Seyh Edebali University have described quinazolinone derivative compounds acting as EGFR (HER1; erbB1) inhibitors and apoptosis inducers reported to be useful for the treatment of lung cancer.
Signet Therapeutics Co. Ltd. has divulged α, β-unsaturated amide compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Researchers from Circle Pharma Inc. have presented preclinical data for CID-078, a novel orally bioavailable cyclin A/B Rxl macrocycle being developed for the treatment of patients with lung cancer. CID-078 was developed as a macrocycle that binds to the hydrophobic patch of cyclins A and B and blocks RxL-dependent interactions of proteins, such as that of E2F1 with cyclin A-CDK2 and Myt1 with cyclin B-CDK1.
